65 filings
8-K
IMNM
Immunome, Inc.
12 Aug 24
Immunome Reports Second Quarter 2024 Financial Results and Provides Business Update
4:05pm
8-K
IMNM
Immunome, Inc.
13 Jun 24
Submission of Matters to a Vote of Security Holders
4:05pm
8-K
IMNM
Immunome, Inc.
14 May 24
Immunome Reports First Quarter 2024 Financial Results and Provides Business Update
8:02am
8-K
IMNM
Immunome, Inc.
30 Apr 24
Departure of Directors or Certain Officers
4:01pm
8-K
IMNM
Immunome, Inc.
25 Apr 24
Departure of Directors or Certain Officers
4:01pm
8-K
0z4rum0as1 mla
28 Mar 24
Immunome Reports Full-Year 2023 Financial Results and Provides Update on Recently Acquired Assets
4:04pm
8-K
zpe4s13oc89n6dll3l
26 Mar 24
Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala
8:05am
8-K
9nb7n2cnc35k6nd
14 Feb 24
Other Events
4:11pm
8-K
1daj6wsu
13 Feb 24
Results of Operations and Financial Condition
4:10pm
8-K
eq24 a85j2fp
6 Feb 24
Immunome To Acquire AL102, A Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals
8:05am
8-K
i8j 052ft3
31 Jan 24
Departure of Directors or Certain Officers
9:18pm
8-K
t5kusgm
11 Jan 24
Regulation FD Disclosure
5:27pm
8-K
o3a1eaodrcuwa57kd18d
8 Jan 24
Entry into a Material Definitive Agreement
7:05am
8-K
jbc9 x14b
2 Jan 24
Departure of Directors or Certain Officers
8:05am
8-K
y8q vawohqk
29 Dec 23
Departure of Directors or Certain Officers
5:00pm
8-K
5t4c8nw
26 Dec 23
Other Events
8:35am
8-K/A
v6o15twj b3v8tru
22 Nov 23
Report of Independent Auditors
4:02pm
8-K
b0fxny0qv kmtkfh71
15 Nov 23
Regulation FD Disclosure
6:03am
8-K
7to78 sjd3
9 Nov 23
Immunome Reports Third Quarter 2023 Financial Results
4:52pm
8-K
riquofy529cgvzf
8 Nov 23
Departure of Directors or Certain Officers
8:30am